Organization (Hospital)
Liaoning Cancer Hospital & Institute
ClinicalTrials.gov lists Liaoning Cancer Hospital & Institute as lead sponsor of 23 trials. It has 44 active development programs and 22 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 7 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 9 in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Liaoning Cancer Hospital & Institute: 23 lead-sponsored trials and 1 legal-entity registration.
Disease areas (38)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 21 |
| Breast Neoplasms | 15 |
| Lung Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Rectal Neoplasms | 9 |
Showing 5 of 38 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 14 |
| 2024 | 12 |
| 2023 | 9 |
| 2022 | 14 |
| 2021 | 8 |
| 2020 | 7 |
| 2019 | 7 |
| 2018 | 7 |
| 2017 | 10 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (44)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| 3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference. | Lung Neoplasms | Phase 2 | 1 |
| Cisplatin Or Carboplatin | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
| AG chemotherapy | Breast Neoplasms | Phase 2 | 1 |
| 3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference. | Carcinoma, Non-Small-Cell Lung | Phase 2 | 1 |
| Cisplatin Or Carboplatin | Lung Neoplasms | Phase 2 | 1 |
Showing 5 of 44 active programs.
Approved assets (22)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| SOX Chemotherapy | 3 |
| SOX plus PD-1 inhibitor | 3 |
| PD -1/PD-L1 monoclonal antibody | 1 |
| Tegafur-Ugotex or Capecitabine | 1 |
| Chidamide+ Fulvestrant | 1 |
Showing 5 of 22 approved assets.
Journals published in (71)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 9 |
| Lancet (London, England) | 5 |
| Annals of surgery | 4 |
| BMC cancer | 3 |
| European journal of cancer (Oxford, England : 1990) | 3 |
Showing 5 of 71 journals.
Organization relationships (66)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| West China Hospital | Co sponsors trial with | 7 |
| Shengjing Hospital | Co sponsors trial with | 5 |
| Jiangsu Cancer Institute & Hospital | Co sponsors trial with | 4 |
| Peking University Cancer Hospital & Institute | Co sponsors trial with | 4 |
| Shanghai Zhongshan Hospital | Co sponsors trial with | 4 |
Showing 5 of 66 relationships.
Latest dated events (110)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 110 events.
Biomarker capability evidence (253)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 253 evidence rows.
Biomarkers this organization publishes on (148)
Shown in this order: most publications first.
Showing 5 of 148 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.